



US008536130B2

(12) **United States Patent**
Christoph et al.

(10) **Patent No.:** **US 8,536,130 B2**
(45) **Date of Patent:** **Sep. 17, 2013**

(54) **USE OF 1
PHENYL-3-DIMETHYLAMINO-PROPANE
COMPOUNDS FOR TREATING
NEUROPATHIC PAIN**

(75) Inventors: **Thomas Christoph**, Aachen (DE);
Elmar Friderichs, Stolberg (DE);
Babette-Yvonne Koegel,
Langerwehe-Hamich (DE); **Murielle
Meen**, Ayguesvives (FR)

(73) Assignee: **Gruenthal GmbH**, Aachen (DE)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 195 days.

(21) Appl. No.: **12/850,208**

(22) Filed: **Aug. 4, 2010**

(65) **Prior Publication Data**

US 2010/0311842 A1 Dec. 9, 2010

Related U.S. Application Data

(63) Continuation of application No. 12/045,830, filed on
Mar. 11, 2008, now abandoned.

(60) Provisional application No. 60/906,220, filed on Mar.
12, 2007.

(30) **Foreign Application Priority Data**

Mar. 12, 2007 (DE) 10 2007 012 165

(51) **Int. Cl.**
A61K 38/00 (2006.01)
A61K 31/275 (2006.01)

(52) **U.S. Cl.**
USPC **514/18.2**; 514/529; 514/646; 514/452;
514/456; 514/434

(58) **Field of Classification Search**
USPC 514/18.2, 529, 646, 452, 456, 434
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,248,737 B1 6/2001 Buschmann et al.
6,344,558 B1 2/2002 Buschmann et al.

FOREIGN PATENT DOCUMENTS

DE 44 26 245 A1 2/1996
WO WO 2004/047823 A1 6/2004
WO WO 2007/128413 A1 11/2007

OTHER PUBLICATIONS

Tzhentke et al., The Journal of Pain, vol. 7, Issue 4, supplemental p.
S26, Abstract (687), Apr. 2006.
Dworkin et al., Archives of Neurology, vol. 60, Nov. 2003, pp. 1524-
1534.
Tzhentke et al., Drugs of the Future, 2006, vol. 3, Issue 12, p. 1053,
Abstract.
Tapentadol Structure Compound 10390, The Merck Index, 14th Edi-
tion, 2006, retrieved from Internet on Jan. 29, 2010, URL: [http://
www.knovel.com/web/portal/basic_search/display](http://www.knovel.com/web/portal/basic_search/display).
Christoph et al., *Tapentadol, but not morphine, selectively inhibits
disease-related thermal hyperalgesia in a mouse model of diabetic
neuropathic pain*, Neuroscience Letters 470 (2010) 91-94.
German Search Report, 4 pages.
International Search Report, 4 pages.
Translation of Written Opinion of the International Searching
Authority, 5 pages.
Schwartz, Sherwyn et al., Safety and efficacy of tapentadol ER in
patients with painful diabetic peripheral neuropathy: results of a
randomized-withdrawal, placebo-controlled trial, Current Medical
Research & Opinion, vol. 27, No. 1, 2011, pp. 151-162.
Tzhentke, Thomas et al., Tapentadol HCL: In Vitro and In Vivo
Studies on the Dual Mechanism of Action Underlying its Broad
Analgesic Profile, American Academy of Pain Medicine, 23rd Annual
Meeting, Feb. 7-10, 2007.
Tzhentke, T. M. et al., Tapentadol Hydrochloride. In: Drugs
Future, 2006, vol. 31, S. 1053-1061; Zusammenf., F. 1056, Tab. III.

Primary Examiner — Savitha Rao

(74) *Attorney, Agent, or Firm* — Crowell & Moring LLP

(57) **ABSTRACT**

Use of 1-phenyl-3-dimethylaminopropane compounds for
the production of medicaments for treating neuropathic pain,
preferably polyneuropathic pain, also preferably diabetic
neuropathic pain, more preferably diabetic peripheral neuro-
pathic pain, and furthermore preferably for treating diabetic
peripheral neuropathy.

6 Claims, No Drawings